Marshall Wace LLP Has $214,000 Stock Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT)

Marshall Wace LLP reduced its holdings in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) by 32.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,868 shares of the company’s stock after selling 16,200 shares during the quarter. Marshall Wace LLP owned 0.18% of Nuvectis Pharma worth $214,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in NVCT. Baxter Bros Inc. bought a new position in Nuvectis Pharma in the 2nd quarter valued at about $79,000. Blue Zone Wealth Advisors LLC bought a new position in shares of Nuvectis Pharma in the first quarter valued at approximately $118,000. Renaissance Technologies LLC lifted its holdings in shares of Nuvectis Pharma by 20.7% in the second quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock valued at $472,000 after purchasing an additional 12,800 shares in the last quarter. Baldwin Brothers LLC MA boosted its position in shares of Nuvectis Pharma by 9.4% during the second quarter. Baldwin Brothers LLC MA now owns 168,630 shares of the company’s stock valued at $1,067,000 after buying an additional 14,500 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Nuvectis Pharma by 1.5% during the first quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock worth $2,450,000 after buying an additional 4,517 shares in the last quarter. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Nuvectis Pharma Stock Performance

Nuvectis Pharma stock opened at $6.40 on Friday. Nuvectis Pharma, Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $12.10. The firm’s 50-day simple moving average is $6.55 and its 200 day simple moving average is $6.68. The stock has a market cap of $117.48 million, a PE ratio of -4.54 and a beta of 0.46.

Nuvectis Pharma (NASDAQ:NVCT) last posted its earnings results on Tuesday, August 6th. The company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). As a group, analysts predict that Nuvectis Pharma, Inc. will post -1.05 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.